{"organizations": [], "uuid": "94c16d6f4c205a0d7aeb3f613930dd4532eaf2e5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alexion-says-no-compulsory-license/brief-alexion-says-no-compulsory-license-of-soliris-was-requested-or-granted-in-brazil-idUSFWN1RX0ZF", "country": "US", "domain_rank": 408, "title": "BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-20T22:40:00.000+03:00", "replies_count": 0, "uuid": "94c16d6f4c205a0d7aeb3f613930dd4532eaf2e5"}, "author": "", "url": "https://www.reuters.com/article/brief-alexion-says-no-compulsory-license/brief-alexion-says-no-compulsory-license-of-soliris-was-requested-or-granted-in-brazil-idUSFWN1RX0ZF", "ord_in_thread": 0, "title": "BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil", "locations": [], "entities": {"persons": [], "locations": [{"name": "soliris", "sentiment": "none"}, {"name": "brazil", "sentiment": "none"}, {"name": "brazil", "sentiment": "none"}], "organizations": [{"name": "alexion", "sentiment": "none"}, {"name": "alexion pharmaceuticals inc", "sentiment": "none"}, {"name": "alexion pharmaceuticals", "sentiment": "none"}, {"name": "granted in brazil reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "alexion pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 20, 2018 / 7:40 PM / Updated 6 minutes ago BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil Reuters Staff \nApril 20 (Reuters) - Alexion Pharmaceuticals Inc: \n* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRISÂ® (ECULIZUMAB) \n* ALEXION PHARMACEUTICALS - ALEXION WOULD LIKE TO CLARIFY THAT NO COMPULSORY LICENSE OF SOLIRIS WAS REQUESTED OR GRANTED IN BRAZIL \n* ALEXION PHARMACEUTICALS INC - CONTINUES TO HAVE PATENT APPLICATIONS PENDING IN BRAZIL THAT WOULD PROVIDE ADDITIONAL PROTECTION TO SOLIRIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-20T22:40:00.000+03:00", "crawled": "2018-04-20T22:58:02.003+03:00", "highlightTitle": ""}